Determining the prevalence of AR variants in different clinical states of prostate cancer has been challenged by requirements for well-preserved frozen tissue samples for transcript-based analyses, and the lack of antibodies capable of specifically detecting most AR variant proteins. This evidence concerns the gene AR and prostate carcinoma.